Rheumatic Manifestations of Diabetes Mellitus

Rheumatic Disease Clinics of North America

Volumn 36, Issue 4, 2010, Pages 681-699

  Lebiedz Odrobina, Dorota ^a   Kay, Jonathan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Advanced glycation end products; Diabetes mellitus; Hand; Joint; Muscle; Rheumatic manifestations; Shoulder

Indexed keywords

ADIPOCYTOKINE; ADVANCED GLYCATION END PRODUCT; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; COLLAGENASE; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SORBINIL;

ADULT RESPIRATORY DISTRESS SYNDROME; ANKYLOSING HYPEROSTOSIS; CARPAL TUNNEL SYNDROME; CHRONIC DISEASE; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME; DIABETES MELLITUS; DIABETIC MUSCLE INFARCTION; DISEASE ASSOCIATION; DRUG ABSORPTION; DUPUYTREN CONTRACTURE; EPIDERMOLYSIS; FROZEN SHOULDER; GLYCEMIC CONTROL; GOUT; HUMAN; HUMEROSCAPULAR PERIARTHRITIS; JOINT HYPOMOBILITY; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASE; NEUROPATHIC JOINT DISEASE; OBSERVATIONAL STUDY; OSTEOARTHRITIS; OSTEOARTHROPATHY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRIORITY JOURNAL; PSEUDOGOUT; REVIEW; RHEUMATIC DISEASE; STEVENS JOHNSON SYNDROME; SURGICAL TECHNIQUE; TENDINITIS; TENDON RUPTURE; TRIGGER FINGER;

BURSITIS; COMORBIDITY; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; PREVALENCE; RANGE OF MOTION, ARTICULAR; RHEUMATIC DISEASES; SHOULDER; SHOULDER IMPINGEMENT SYNDROME; UNITED STATES;

EID: 78449253252     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2010.09.008     Document Type: Review

References (132)

1. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006, 29(6):1263-1268.
2. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(Suppl 1):S5-S10.
3. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol 2005, 4(4):198-203.
4. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28(9):2289-2304.
5. Crispin J.C., Alcocer-Varela J. Rheumatic manifestations of diabetes mellitus. Am J Med 2003, 114:753-757.
6. Arkkila P.E., Gautier J.F. Musculoskeletal disorders in diabetes mellitus: an update. Best Pract Res Clin Rheumatol 2003, 17(6):945-970.
7. Cagliero E. Rheumatic manifestations of diabetes mellitus. Curr Rheumatol Rep 2003, 5(3):189-194.
8. Ardic F., Soyupek F., Kahraman Y., et al. The musculoskeletal complications seen in type II diabetics: predominance of hand involvement. Clin Rheumatol 2003, 22(3):229-233.
9. Cagliero E., Apruzzese W., Perlmutter G.S., et al. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. Am J Med 2002, 112(6):487-490.
10. Lundbaek K. Stiff hands in long-term diabetes. Acta Med Scand 1957, 158:447-451.
11. Rosenbloom A.L., Frias J.L. Diabetes mellitus, short stature and joint stiffness - a new syndrome. Clin Res 1974, 22:92A.
12. Rosenbloom A.L., Silverstein J.H. Connective tissue and joint disease in diabetes mellitus. Endocrinol Metab Clin North Am 1996, 25(2):473-483.
13. Rosenbloom A.L. Limitation of finger joint mobility in diabetes mellitus. J Diabet Complications 1989, 3(2):77-87.
14. Pal B., Anderson J., Dick W.C., et al. Limitation of joint mobility and shoulder capsulitis in insulin- and non-insulin-dependent diabetes mellitus. Br J Rheumatol 1986, 25(2):147-151.
15. Rosenbloom A.L., Silverstein J.H., Lezotte D.C., et al. Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med 1981, 305(4):191-194.
16. Fitzcharles M.A., Duby S., Waddell R.W., et al. Limitation of joint mobility (cheiroarthropathy) in adult noninsulin-dependent diabetic patients. Ann Rheum Dis 1984, 43(2):251-254.
17. Starkman H.S., Gleason R.E., Rand L.I., et al. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann Rheum Dis 1986, 45(2):130-135.
18. Arkkila P.E., Kantola I.M., Viikari J.S., et al. Limited joint mobility is associated with the presence but does not predict the development of microvascular complications in type 1 diabetes. Diabet Med 1996, 13(9):828-833.
19. Buckingham B., Perejda A.J., Sandborg C., et al. Skin, joint, and pulmonary changes in type I diabetes mellitus. Am J Dis Child 1986, 140(5):420-423.
20. Lawson P.M., Maneschi F., Kohner E.M. The relationship of hand abnormalities to diabetes and diabetic retinopathy. Diabetes Care 1983, 6(2):140-143.
21. Jennings A.M., Milner P.C., Ward J.D. Hand abnormalities are associated with the complications of diabetes in type 2 diabetes. Diabet Med 1989, 6(1):43-47.
22. Arkkila P.E., Kantola I.M., Viikari J.S. Limited joint mobility in type 1 diabetic patients: correlation to other diabetic complications. J Intern Med 1994, 236(2):215-223.
23. Arkkila P.E., Kantola I.M., Viikari J.S., et al. Shoulder capsulitis in type I and II diabetic patients: association with diabetic complications and related diseases. Ann Rheum Dis 1996, 55(12):907-914.
24. McCance D.R., Crowe G., Quinn M.J., et al. Incidence of microvascular complications in type 1 diabetic subjects with limited joint mobility: a 10-year prospective study. Diabet Med 1993, 10(9):807-810.
25. Arkkila P.E., Kantola I.M., Viikari J.S. Limited joint mobility in non-insulin-dependent diabetic (NIDDM) patients: correlation to control of diabetes, atherosclerotic vascular disease, and other diabetic complications. J Diabetes Complications 1997, 11(4):208-217.
26. Vukovic J., Dumic M., Radica A., et al. Risk factors for expression and progression of limited joint mobility in insulin-dependent childhood diabetes. Acta Diabetol 1996, 33(1):15-18.
27. Silverstein J.H., Gordon G., Pollock B.H., et al. Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. J Pediatr 1998, 132(6):944-947.
28. Aydeniz A., Gursoy S., Guney E. Which musculoskeletal complications are most frequently seen in type 2 diabetes mellitus?. J Int Med Res 2008, 36(3):505-511.
29. Lindsay J.R., Kennedy L., Atkinson A.B., et al. Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic population over a 20-year period. Diabetes Care 2005, 28(3):658-661.
30. Harris M.I., Klein R., Welborn T.A., et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992, 15(7):815-819.
31. Infante J.R., Rosenbloom A.L., Silverstein J.H., et al. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr 2001, 138(1):33-37.
32. Eaton R.P., Sibbitt W.L., Harsh A. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients. JAMA 1985, 253(10):1437-1440.
33. Krans H.M. Recent clinical experience with aldose reductase inhibitors. J Diabetes Complications 1992, 6(1):39-44.
34. Kameyama M., Meguro S., Funae O., et al. The presence of limited joint mobility is significantly associated with multiple digit involvement by stenosing flexor tenosynovitis in diabetics. J Rheumatol 2009, 36(8):1686-1690.
35. Yosipovitch G., Yosipovitch Z., Karp M., et al. Trigger finger in young patients with insulin dependent diabetes. J Rheumatol 1990, 17(7):951-952.
36. Chammas M., Bousquet P., Renard E., et al. Dupuytren's disease, carpal tunnel syndrome, trigger finger, and diabetes mellitus. J Hand Surg Am 1995, 20(1):109-114.
37. Ryzewicz M., Wolf J.M. Trigger digits: principles, management, and complications. J Hand Surg Am 2006, 31(1):135-146.
38. Baumgarten K.M., Gerlach D., Boyer M.I. Corticosteroid injection in diabetic patients with trigger finger. A prospective, randomized, controlled double-blinded study. J Bone Joint Surg Am 2007, 89(12):2604-2611.
39. Wang A.A., Hutchinson D.T. The effect of corticosteroid injection for trigger finger on blood glucose level in diabetic patients. J Hand Surg Am 2006, 31(6):979-981.
40. Griggs S.M., Weiss A.P., Lane L.B., et al. Treatment of trigger finger in patients with diabetes mellitus. J Hand Surg Am 1995, 20(5):787-789.
41. Stahl S., Kanter Y., Karnielli E. Outcome of trigger finger treatment in diabetes. J Diabetes Complications 1997, 11(5):287-290.
42. Noble J., Heathcote J.G., Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br 1984, 66(3):322-325.
43. Loos B., Puschkin V., Horch R.E. 50 years experience with Dupuytren's contracture in the Erlangen University Hospital-a retrospective analysis of 2919 operated hands from 1956 to 2006. BMC Musculoskelet Disord 2007, 8:60.
44. Arkkila P.E., Kantola I.M., Viikari J.S., et al. Dupuytren's disease in type 1 diabetic patients: a five-year prospective study. Clin Exp Rheumatol 1996, 14(1):59-65.
45. Hurst L.C., Badalamente M.A., Hentz V.R., et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009, 361(10):968-979.
46. Reeves B. The natural history of the frozen shoulder syndrome. Scand J Rheumatol 1975, 4(4):193-196.
47. Codman EA. Tendinitis of the short rotators. In: Codman EA, editor. The shoulder: rupture of the supraspinatus tendon and other lesions in or about the subacromial bursa. Boston: Thomas Todd Co; 1934. p. 216-24. Chapter VII.
48. Neviaser J. Adhesive capsulitis of the shoulder. J Bone Joint Surg Am 1945, 27:211-222.
49. Bridgman J.F. Periarthritis of the shoulder and diabetes mellitus. Ann Rheum Dis 1972, 31(1):69-71.
50. Balci N., Balci M.K., Tuzuner S. Shoulder adhesive capsulitis and shoulder range of motion in type II diabetes mellitus: association with diabetic complications. J Diabetes Complications 1999, 13(3):135-140.
51. Ramchurn N., Mashamba C., Leitch E., et al. Upper limb musculoskeletal abnormalities and poor metabolic control in diabetes. Eur J Intern Med 2009, 20(7):718-721.
52. Bunker T.D., Anthony P.P. The pathology of frozen shoulder. A Dupuytren-like disease. J Bone Joint Surg Br 1995, 77(5):677-683.
53. Bunker T.D., Reilly J., Baird K.S., et al. Expression of growth factors, cytokines and matrix metalloproteinases in frozen shoulder. J Bone Joint Surg Br 2000, 82(5):768-773.
54. Griggs S.M., Ahn A., Green A. Idiopathic adhesive capsulitis. A prospective functional outcome study of nonoperative treatment. J Bone Joint Surg Am 2000, 82-A(10):1398-1407.
55. Ogilvie-Harris D.J., Myerthall S. The diabetic frozen shoulder: arthroscopic release. Arthroscopy 1997, 13(1):1-8.
56. Cinar M., Akpinar S., Derincek A., et al. Comparison of arthroscopic capsular release in diabetic and idiopathic frozen shoulder patients. Arch Orthop Trauma Surg 2010, 130(3):401-406.
57. Sheridan M.A., Hannafin J.A. Upper extremity: emphasis on frozen shoulder. Orthop Clin North Am 2006, 37(4):531-539.
58. Buckingham B.A., Uitto J., Sandborg C., et al. Scleroderma-like changes in insulin-dependent diabetes mellitus: clinical and biochemical studies. Diabetes Care 1984, 7(2):163-169.
59. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005, 11(18):2279-2299.
60. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009, 13(6):534-539.
61. Monnier V.M., Vishwanath V., Frank K.E., et al. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986, 314(7):403-408.
62. Mavrikakis M.E., Drimis S., Kontoyannis D.A., et al. Calcific shoulder periarthritis (tendinitis) in adult onset diabetes mellitus: a controlled study. Ann Rheum Dis 1989, 48(3):211-214.
63. Jung Y., Hohmann T.C., Gerneth J.A., et al. Diabetic hand syndrome. Metabolism 1971, 20(11):1008-1015.
64. Geoghegan J.M., Clark D.I., Bainbridge L.C., et al. Risk factors in carpal tunnel syndrome. J Hand Surg Br 2004, 29(4):315-320.
65. Becker J., Nora D.B., Gomes I., et al. An evaluation of gender, obesity, age and diabetes mellitus as risk factors for carpal tunnel syndrome. Clin Neurophysiol 2002, 113(9):1429-1434.
66. Perkins B.A., Olaleye D., Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care 2002, 25(3):565-569.
67. Ozkul Y., Sabuncu T., Kocabey Y., et al. Outcomes of carpal tunnel release in diabetic and non-diabetic patients. Acta Neurol Scand 2002, 106(3):168-172.
68. Yasuda H., Terada M., Maeda K., et al. Diabetic neuropathy and nerve regeneration. Prog Neurobiol 2003, 69(4):229-285.
69. Kennedy J.M., Zochodne D.W. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst 2005, 10(2):144-157.
70. Greene D.A., Lattimer S.A., Sima A.A. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987, 316(10):599-606.
71. Low P.A., Tuck R.R., Dyck P.J., et al. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci U S A 1984, 81(21):6894-6898.
72. Chiarelli F., Santilli F., Mohn A. Role of growth factors in the development of diabetic complications. Horm Res 2000, 53(2):53-67.
73. Thomsen N.O., Cederlund R., Rosen I., et al. Clinical outcomes of surgical release among diabetic patients with carpal tunnel syndrome: prospective follow-up with matched controls. J Hand Surg Am 2009, 34(7):1177-1187.
74. Mondelli M., Padua L., Reale F., et al. Outcome of surgical release among diabetics with carpal tunnel syndrome. Arch Phys Med Rehabil 2004, 85(1):7-13.
75. Angervall L., Stener B. Tumoriform focal muscular degeneration in two diabetic patients. Diabetologia 1965, 1:39-42.
76. Trujillo-Santos A.J. Diabetic muscle infarction: an underdiagnosed complication of long-standing diabetes. Diabetes Care 2003, 26(1):211-215.
77. Kapur S., McKendry R.J. Treatment and outcomes of diabetic muscle infarction. J Clin Rheumatol 2005, 11(1):8-12.
78. Kapur S., Brunet J.A., McKendry R.J. Diabetic muscle infarction: case report and review. J Rheumatol 2004, 31(1):190-194.
79. Kattapuram T.M., Suri R., Rosol M.S., et al. Idiopathic and diabetic skeletal muscle necrosis: evaluation by magnetic resonance imaging. Skeletal Radiol 2005, 34(4):203-209.
80. Chester C.S., Banker B.Q. Focal infarction of muscle in diabetics. Diabetes Care 1986, 9(6):623-630.
81. Bjornskov E.K., Carry M.R., Katz F.H., et al. Diabetic muscle infarction: a new perspective on pathogenesis and management. Neuromuscul Disord 1995, 5(1):39-45.
82. Palmer G.W., Greco T.P. Diabetic thigh muscle infarction in association with antiphospholipid antibodies. Semin Arthritis Rheum 2001, 30(4):272-280.
83. Charcot J. Sur quelques arthropathies qui paraissent dependre d'une lesion du cerveau ou de la moelle epiniere. Arch Physiol Norm Pathol 1868, 1:161-178.
84. Lee L., Blume P.A., Sumpio B. Charcot joint disease in diabetes mellitus. Ann Vasc Surg 2003, 17(5):571-580.
85. Sinha S., Munichoodappa C.S., Kozak G.P. Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). Medicine (Baltimore) 1972, 51(3):191-210.
86. Brower A.C., Allman R.M. Pathogenesis of the neurotrophic joint: neurotraumatic vs. neurovascular. Radiology 1981, 139(2):349-354.
87. Jeffcoate W.J. Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev 2008, 24(Suppl 1):S62-S65.
88. Chantelau E., Richter A., Ghassem-Zadeh N., et al. " Silent" bone stress injuries in the feet of diabetic patients with polyneuropathy: a report on 12 cases. Arch Orthop Trauma Surg 2007, 127(3):171-177.
89. Ulbrecht J.S., Wukich D.K. The Charcot foot: medical and surgical therapy. Curr Diab Rep 2008, 8(6):444-451.
90. Lipman B.T., Collier B.D., Carrera G.F., et al. Detection of osteomyelitis in the neuropathic foot: nuclear medicine, MRI and conventional radiography. Clin Nucl Med 1998, 23(2):77-82.
91. Palestro C.J., Mehta H.H., Patel M., et al. Marrow versus infection in the Charcot joint: indium-111 leukocyte and technetium-99m sulfur colloid scintigraphy. J Nucl Med 1998, 39(2):346-350.
92. Seabold J.E., Flickinger F.W., Kao S.C., et al. Indium-111-leukocyte/technetium-99 m-MDP bone and magnetic resonance imaging: difficulty of diagnosing osteomyelitis in patients with neuropathic osteoarthropathy. J Nucl Med 1990, 31(5):549-556.
93. Forestier J., Rotes-Querol J. Senile ankylosing hyperostosis of the spine. Ann Rheum Dis 1950, 9(4):321-330.
94. Resnick D., Niwayama G. Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology 1976, 119(3):559-568.
95. Julkunen H., Heinonen O.P., Pyorala K. Hyperostosis of the spine in an adult population. Its relation to hyperglycaemia and obesity. Ann Rheum Dis 1971, 30(6):605-612.
96. Julkunen H., Karava R., Viljanen V. Hyperostosis of the spine in diabetes mellitus and acromegaly. Diabetologia 1966, 2(2):123-126.
97. Hajkova Z., Streda A., Skrha F. Hyperostotic spondylosis and diabetes mellitus. Ann Rheum Dis 1965, 24(6):536-543.
98. Kiss C., Szilagyi M., Paksy A., et al. Risk factors for diffuse idiopathic skeletal hyperostosis: a case-control study. Rheumatology (Oxford) 2002, 41(1):27-30.
99. Mader R., Dubenski N., Lavi I. Morbidity and mortality of hospitalized patients with diffuse idiopathic skeletal hyperostosis. Rheumatol Int 2005, 26(2):132-136.
100. Mata S., Fortin P.R., Fitzcharles M.A., et al. A controlled study of diffuse idiopathic skeletal hyperostosis. Clinical features and functional status. Medicine (Baltimore) 1997, 76(2):104-117.
101. Sencan D., Elden H., Nacitarhan V., et al. The prevalence of diffuse idiopathic skeletal hyperostosis in patients with diabetes mellitus. Rheumatol Int 2005, 25(7):518-521.
102. Daragon A., Mejjad O., Czernichow P., et al. Vertebral hyperostosis and diabetes mellitus: a case-control study. Ann Rheum Dis 1995, 54(5):375-378.
103. Vezyroglou G, Mitropoulos A, Antoniadis C A metabolic syndrome in diffuse idiopathic skeletal hyperostosis. A controlled study. J Rheumatol 1996, 23(4):672-676.
104. Mader R., Novofestovski I., Adawi M., et al. Metabolic syndrome and cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin Arthritis Rheum 2009, 38(5):361-365.
105. Littlejohn G.O., Smythe H.A. Marked hyperinsulinemia after glucose challenge in patients with diffuse idiopathic skeletal hyperostosis. J Rheumatol 1981, 8(6):965-968.
106. Denko C.W., Boja B., Moskowitz R.W. Growth promoting peptides in osteoarthritis and diffuse idiopathic skeletal hyperostosis-insulin, insulin-like growth factor-I, growth hormone. J Rheumatol 1994, 21(9):1725-1730.
107. Littlejohn G.O. Insulin and new bone formation in diffuse idiopathic skeletal hyperostosis. Clin Rheumatol 1985, 4(3):294-300.
108. Ernst M., Rodan G.A. Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology 1990, 127(2):807-814.
109. Utsinger P.D. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis 1985, 11(2):325-351.
110. Al-Herz A., Snip J.P., Clark B., et al. Exercise therapy for patients with diffuse idiopathic skeletal hyperostosis. Clin Rheumatol 2008, 27(2):207-210.
111. Rathmann W., Funkhouser E., Dyer A.R., et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998, 8(4):250-261.
112. Choi H.K., Ford E.S. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007, 120(5):442-447.
113. Choi H.K., Ford E.S., Li C., et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007, 57(1):109-115.
114. Niskanen L., Laaksonen D.E., Lindstrom J., et al. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care 2006, 29(3):709-711.
115. Choi H.K., De Vera M.A., Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008, 47(10):1567-1570.
116. Boss G.R., Seegmiller J.E. Hyperuricemia and gout: classification, complications and management. N Engl J Med 1979, 300:1459-1468.
117. Facchini F., Chen Y.D., Hollenbeck C.B., et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266(21):3008-3011.
118. Ter Maaten J.C., Voorburg A., Heine R.J., et al. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 1997, 92(1):51-58.
119. Muscelli E., Natali A., Bianchi S., et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996, 9(8):746-752.
120. McCarty D.J., Silcox D.C., Coe F., et al. Diseases associated with calcium pyrophosphate dihydrate crystal deposition. Am J Med 1974, 56(5):704-714.
121. Alexander G.M., Dieppe P.A., Doherty M., et al. Pyrophosphate arthropathy: a study of metabolic associations and laboratory data. Ann Rheum Dis 1982, 41(4):377-381.
122. Jones A.C., Chuck A.J., Arie E.A., et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992, 22(3):188-202.
123. Cooper C., Inskip H., Croft P., et al. Individual risk factors for hip osteoarthritis: obesity, hip injury, and physical activity. Am J Epidemiol 1998, 147(6):516-522.
124. Felson D.T., Anderson J.J., Naimark A., et al. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med 1988, 109(1):18-24.
125. Cooper C., Snow S., McAlindon T.E., et al. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum 2000, 43(5):995-1000.
126. Niu J., Zhang Y.Q., Torner J., et al. Is obesity a risk factor for progressive radiographic knee osteoarthritis?. Arthritis Rheum 2009, 61(3):329-335.
127. Burner T.W., Rosenthal A.K. Diabetes and rheumatic diseases. Curr Opin Rheumatol 2009, 21(1):50-54.
128. Verzijl N., DeGroot J., Ben Z.C., et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002, 46(1):114-123.
129. DeGroot J., Verzijl N., Wenting-Van Wijk M.J., et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum 2001, 44(11):2562-2571.
130. DeGroot J., Verzijl N., Bank R.A., et al. Age-related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic glycation. Arthritis Rheum 1999, 42(5):1003-1009.
131. DeGroot J., Verzijl N., Jacobs K.M., et al. Accumulation of advanced glycation endproducts reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage. Osteoarthritis Cartilage 2001, 9(8):720-726.
132. Gandhi R., Takahashi M., Syed K., et al. Relationship between body habitus and joint leptin levels in a knee osteoarthritis population. J Orthop Res 2010, 28(3):329-333.